Thermo Fisher Scientific TMO Specialty Diagnostics — Operating Income (Loss)

Other segment segments

Similar metrics at other companies

DHRDiagnostics — Operating Income (Loss)

$416M-24.9%

AMRXSpecialty — Operating Income (Loss)

$54.86M+54.6%

CRSSpecialty Alloys Operations — Operating Income (Loss)

$229.7M+34.6%

GTL

GTLSSpecialty Products — Operating Income (Loss)

$8.4M-82.6%

APGSpecialty Services — Operating Income (Loss)

$39M+34.5%

BCPCSpecialty Products — Operating Income (Loss)

$11.94M+24.5%

FAQ

What is Thermo Fisher Scientific's specialty diagnostics — operating income (loss)?

Thermo Fisher Scientific (TMO) reported specialty diagnostics — operating income (loss) of $334M in Q2 2026.

How has Thermo Fisher Scientific's specialty diagnostics — operating income (loss) changed year-over-year?

Thermo Fisher Scientific's specialty diagnostics — operating income (loss) increased by 8.8% year-over-year, from $307M to $334M.

What is the long-term trend for Thermo Fisher Scientific's specialty diagnostics — operating income (loss)?

Over 4 years (2021 to 2025), Thermo Fisher Scientific's specialty diagnostics — operating income (loss) has grown at a -0.5% compound annual growth rate (CAGR), from $1.28B to $1.26B.

What does specialty diagnostics — operating income (loss) mean?

The profit or loss generated by the Specialty Diagnostics segment after deducting all operating expenses, including cost of revenues, SG&A, and R&D, from total segment revenue. This is the primary measure of the segment's core operational profitability.